The U.S. Food and Drug Administration's (FDA) Biomarker Qualification Program (BQP) is currently reviewing C-Path's Full Qualification Package (FQP) to qualify GLDH as a liver safety biomarker. The ...

Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions of this cell type have hardly been studied to date. Researchers from the German Cancer Research ...

we could potentially halt liver scarring and simultaneously improve liver function, which may be most helpful for patients in advanced disease stages who are not helped by current therapies," adds ...

A Chinese research team has developed an AI tool that predicts liver cancer recurrence risk with 82.2 percent accuracy, according to a study recently published in the journal Nature. Liver cancer ...

Derisking of drug-induced liver injury (DILI) continues to be a challenge for pharmaceutical scientists. Join Michael Hafey, Principal Scientist at Merck, as he discusses how to utilize a two-tiered ...